4
Changes in Ownership
Maze Therapeutics, Inc. Filed Acc 0001415889-25-002956
Director acquired 36,946 shares (conversion)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| HOMCY CHARLES J Director | 2025-02-03 | Conversion | +8,807 | 37,330 | D: show line 1 in the form | ||
| HOMCY CHARLES J Director | 2025-02-03 | Conversion | +20,717 | 58,047 | D: show line 2 in the form | ||
| HOMCY CHARLES J Director | 2025-02-03 | Conversion | +7,422 | 7,422 | I: show line 3 in the form |
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| HOMCY CHARLES J Director | 2025-02-03 | Conversion · Series B Preferred Stock | −72,727 | 0 | D: show line 4 in the form | |||||
| HOMCY CHARLES J Director | 2025-02-03 | Conversion · Series C Preferred Stock | −169,405 | 0 | D: show line 5 in the form | |||||
| HOMCY CHARLES J Director | 2025-02-03 | Conversion · Series D-1 Preferred Stock | −71,564 | 0 | I: show line 6 in the form | |||||
| HOMCY CHARLES J Director | 2024-11-26 | Conversion · Series D-1 Preferred Stock | +71,564 | 7,422 | I: show line 7 in the form | |||||
| HOMCY CHARLES J Director | 2024-11-26 | Conversion · 8% Convertible Note due 2026 | −0 | $78,961.64 | $0 | I: show line 8 in the form | ||||
| HOMCY CHARLES J Director | 2024-12-09 | Grant or award · Stock Option (Right to Buy) | +80,385 | 80,385 | D: show line 9 in the form | |||||
| HOMCY CHARLES J Director | 2024-12-09 | Returned to the company · Stock Option (Right to Buy) | −80,385 | 0 | D: show line 10 in the form | |||||
| HOMCY CHARLES J Director | 2024-12-09 | Grant or award · Stock Option (Right to Buy) | +5,704 | 5,704 | D: show line 11 in the form |
Loading xslF345X05/form4-02042025_090216.xml…